| Literature DB >> 20418386 |
Harold R Collard1, Carolyn S Calfee, Paul J Wolters, Jin Woo Song, Sang-Bum Hong, Sandra Brady, Akitoshi Ishizaka, Kirk D Jones, Talmadge E King, Michael A Matthay, Dong Soon Kim.
Abstract
Little is known about the pathobiology of acute exacerbation of idiopathic pulmonary fibrosis (IPF), a condition that shares clinical and histopathological features with acute lung injury. Plasma biomarkers have been well studied in acute lung injury and have provided insight into the underlying disease mechanism. The objective of this study was to determine the plasma biomarker profile of acute exacerbation of IPF and compare this profile with that of stable IPF and acute lung injury. Plasma was collected from patients with stable IPF, acute exacerbation of IPF, and acute lung injury for measurement of biomarkers of cellular activity/injury (receptor for advanced glycation endproducts, surfactant protein D, KL-6, von Willebrand factor), systemic inflammation (IL-6), and coagulation/fibrinolysis (protein C, thrombomodulin, plasminogen activator inhibitor-1). Plasma from patients with acute exacerbation of IPF showed significant elevations in markers of type II alveolar epithelial cell injury and/or proliferation, endothelial cell injury, and coagulation. This profile differed from the biomarker profile in patients with acute lung injury. These findings support the hypothesis that type II alveolar epithelial cells are centrally involved in the pathobiology of acute exacerbation of IPF. Furthermore, they suggest that acute exacerbation of IPF has a distinct plasma biomarker profile from that of acute lung injury.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20418386 PMCID： PMC2904092 DOI： 10.1152/ajplung.90637.2008
Source DB: PubMed Journal: Am J Physiol Lung Cell Mol Physiol ISSN： 1040-0605 Impact factor: 5.464